These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Evaluation of alpha-fetoprotein concentration in patients with chronic liver diseases]. Wójtowicz-Chomicz K; Cichoz-Lach H; Lis E; Kowalik A; Słomka M Pol Merkur Lekarski; 2012 Jun; 32(192):374-7. PubMed ID: 22891562 [TBL] [Abstract][Full Text] [Related]
3. Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis. Elsammak MY; Amin GM; Khalil GM; Ragab WS; Abaza MM Clin Biochem; 2006 Jun; 39(6):623-9. PubMed ID: 16624274 [TBL] [Abstract][Full Text] [Related]
4. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. Lamerz R; Runge M; Stieber P; Meissner E Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180 [TBL] [Abstract][Full Text] [Related]
6. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Cedrone A; Covino M; Caturelli E; Pompili M; Lorenzelli G; Villani MR; Valle D; Sperandeo M; Rapaccini GL; Gasbarrini G Hepatogastroenterology; 2000; 47(36):1654-8. PubMed ID: 11149026 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164 [TBL] [Abstract][Full Text] [Related]
8. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961 [TBL] [Abstract][Full Text] [Related]
9. Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. Wu JC; Daughaday WH; Lee SD; Hsiao TS; Chou CK; Lin HD; Tsai YT; Chiang BN J Lab Clin Med; 1988 Nov; 112(5):589-94. PubMed ID: 2460570 [TBL] [Abstract][Full Text] [Related]
10. The effectiveness of serum alpha-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma. Peng YC; Chan CS; Chen GH Hepatogastroenterology; 1999; 46(30):3208-11. PubMed ID: 10626187 [TBL] [Abstract][Full Text] [Related]
11. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Mazziotti G; Sorvillo F; Morisco F; Carbone A; Rotondi M; Stornaiuolo G; Precone DF; Cioffi M; Gaeta GB; Caporaso N; Carella C Cancer; 2002 Dec; 95(12):2539-45. PubMed ID: 12467068 [TBL] [Abstract][Full Text] [Related]
12. Differential tumor markers and hepatitis markers profile in liver tumors. Khalifa A; Mady EA; Abadeer N; Kamal A Anticancer Res; 1999; 19(4A):2495-500. PubMed ID: 10470181 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma. Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803 [TBL] [Abstract][Full Text] [Related]
14. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Soresi M; Magliarisi C; Campagna P; Leto G; Bonfissuto G; Riili A; Carroccio A; Sesti R; Tripi S; Montalto G Anticancer Res; 2003; 23(2C):1747-53. PubMed ID: 12820452 [TBL] [Abstract][Full Text] [Related]
15. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674 [TBL] [Abstract][Full Text] [Related]
17. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma. Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443 [TBL] [Abstract][Full Text] [Related]
18. [Subject diagnostic value of detecting a1pha-fetoprotein variants with a new microspincolumn method in hepatocellular carcinoma]. Xu AF; Wang MC; Sui DM; Yuan YH; Chen G; Lou GQ Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):67-9. PubMed ID: 17429541 [TBL] [Abstract][Full Text] [Related]
19. [Decarboxyprothrombin: importance in the diagnosis of hepatocellular carcinoma]. Bon C; Brillard B; Gelineau MC; Mailliavin A; Trépo C; Pichot J Ann Biol Clin (Paris); 1998; 56(2):175-81. PubMed ID: 9754243 [TBL] [Abstract][Full Text] [Related]
20. [Value of the serum measurement of alpha-L-fucosidase in the diagnosis of hepatocarcinoma]. López Vivancos J; Segura RM; Oliva G; Vives L; Pascual C; Vilaseca J Med Clin (Barc); 1989 Sep; 93(7):241-3. PubMed ID: 2478845 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]